2 Hot Biotech IPOs to Consider
Buying a stock right off its initial public offering (IPO) is a gamble, but daring investors know that it can pay off. Especially for companies that are expected to be growing right out of the gate, getting in during the market's initial feeding frenzy sometimes means buying a stock when it's as cheap as it will ever be.
In this vein, Recursion Pharmaceuticals (NASDAQ: RXRX) and Biomea Fusion (NASDAQ: BMEA) are a pair of biotechs that had their IPOs last week, and both have unique value for investors that could make them worth a (speculative) buy.
Recursion's information technology-heavy approach to drug discovery could make it a rising star on the basis of its already extensive list of development collaborations alone. In contrast, Biomea is a more traditional biotech that's taking a highly risky yet deeply innovative approach to make previously intractable conditions into low-hanging fruit. Let's take a closer look at each one to see why they're special.
Source Fool.com